A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast Cancer · Biliary Tract Carcinoma · Ovarian Cancer · Endometrial Cancer · Squamous Non-Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 460 (planned)
- Started
- Oct 18, 2021
- Main results expected
- Sep 29, 2027
- Fully finished
- Sep 29, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The number of patients with adverse events
Measured over: From time of Informed consent to 30 days post last dose (approximately 1 year).
The number of patients with serious adverse events
Measured over: From time of Informed consent to 30 days post last dose (approximately 1 year)
The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.
Measured over: From first dose of study treatment until the end of Cycle 1 (approximately 21 days).
The number of patients with changes from baseline laboratory findings, ECGs and vital signs
Measured over: From time of informed consent to 30 days post last dose (approximately 1 year)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05123482 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC